Takeda Pharmaceutical Co Ltd v. Qilu Pharmaceutical (hainan) Co Ltd

Global Pharma Giant Takeda Sues Generic Maker Qilu to Protect Antiviral Drug LIVTENCITY

On April 17, 2026, Japanese pharmaceutical giant Takeda Pharmaceutical Co. Ltd. filed a patent infringement lawsuit against China-based Qilu Pharmaceutical (hainan) Co Ltd. in the U.S. District Court for the District of New Jersey. Takeda, a major global operating company, is seeking to block Qilu, a large-scale manufacturer of generic drugs and active pharmaceutical ingredients (APIs), from launching a generic version of its antiviral medication, LIVTENCITY® (maribavir). The lawsuit is a classic "Hatch-Waxman" case, triggered by Qilu's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA), signaling its intent to market a generic equivalent of LIVTENCITY before the expiration of Takeda's patents.

The dispute centers on Takeda's U.S. Patent No. 12,527,771, which covers "Viral inhibitors, the synthesis thereof, and intermediates thereto." This patent is understood to protect the specific formulation and/or purity levels of maribavir, the active ingredient in LIVTENCITY. The accused product, LIVTENCITY, is a first-in-class kinase inhibitor approved by the FDA in late 2021. It is prescribed for treating cytomegalovirus (CMV) infections in adult and pediatric transplant recipients when other primary antiviral drugs like ganciclovir have failed. Takeda alleges that Qilu's proposed generic product, if approved and marketed, would infringe upon its patent rights.

The case (2:26-cv-04121) is procedurally significant due to its venue. The District of New Jersey is a highly popular and influential forum for pharmaceutical patent litigation, particularly for ANDA cases, due to its experienced judiciary and specialized local patent rules. In recent years, it has seen a surge in such filings, even surpassing the District of Delaware, another traditional hub for patent disputes. The litigation is notable as it represents a critical step for Takeda in defending the market exclusivity of a key post-transplant therapy. The outcome will determine the timeline for generic competition, which could significantly impact the drug's price and availability for vulnerable patient populations.

Litigation Timeline and Key Developments

As of May 1, 2026, the patent infringement litigation between Takeda and Qilu is in its earliest procedural stages. Having been filed only two weeks prior, on April 17, 2026, the court docket shows minimal activity beyond the initial complaint.

Filing and Initial Pleadings

• 2026-04-17: Complaint Filed
  Takeda Pharmaceutical Co. Ltd. filed a complaint for patent infringement against Qilu Pharmaceutical (hainan) Co Ltd. in the U.S. District Court for the District of New Jersey (D.N.J.). The complaint alleges that Qilu's proposed generic version of LIVTENCITY®, as detailed in its Abbreviated New Drug Application (ANDA), infringes Takeda's U.S. Patent No. 12,527,771. This filing formally initiated the 30-month stay of FDA approval for Qilu's ANDA under the Hatch-Waxman Act.

• Answer and Counterclaims: Not Yet Filed
  As of the current date, Qilu has not yet filed its Answer to Takeda's complaint. Under the Federal Rules of Civil Procedure, a defendant typically has 21 days to respond after being served, a deadline that has not yet passed. It is standard practice in such cases for the defendant's Answer to include counterclaims seeking a declaratory judgment that the asserted patent is invalid and/or not infringed.

Pre-Trial Motions and Other Proceedings

There have been no substantive pre-trial motions filed by either party. Key proceedings that may occur in the coming months but are not yet on the docket include:

• Motions to Dismiss or Transfer: None filed.
• Claim Construction (Markman): The case has not progressed to the claim construction stage, which involves the court interpreting the meaning of disputed patent claim terms.
• Discovery: Formal discovery has not yet commenced.
• Settlement: There is no public record of any settlement discussions.

Parallel PTAB Proceedings

A search of the U.S. Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) records indicates that, as of this date, no petitions for Inter Partes Review (IPR) or Post-Grant Review (PGR) have been filed by Qilu against U.S. Patent No. 12,527,771. It is common for defendants in ANDA litigation to challenge the validity of asserted patents at the PTAB, and such a filing may occur as the district court case proceeds.

Context: Potentially Related Litigation

It is worth noting that some legal news outlets have reported on a separate lawsuit filed by Takeda against Qilu in the same court (D.N.J.) in February 2026. That earlier case allegedly involves the same drug, LIVTENCITY®, but asserts infringement of six different patents. The current case, 2:26-cv-04121, is distinct as it asserts only U.S. Patent No. 12,527,771. The relationship between these two parallel litigations is not yet clear from the public record.

Plaintiff Takeda Enlists Counsel from Gibbons P.C. for LIVTENCITY® Patent Defense

As of May 4, 2026, the court docket for the patent infringement case Takeda v. Qilu (2:26-cv-04121) in the District of New Jersey is not yet publicly populated with counsel appearances beyond the initial filing. However, based on the complaint and established patterns in Takeda's prior patent litigation in this district, counsel from the law firm Gibbons P.C. has been retained to represent the plaintiff.

In Hatch-Waxman ANDA litigation, it is standard for a plaintiff like Takeda to engage both a national, lead counsel firm with deep expertise in pharmaceutical patents and a local New Jersey firm to handle court procedures and provide insights into the specific practices of the D.N.J. judges. While the full legal team, including potential lead counsel from a firm specializing in life sciences, has not formally appeared on the docket, representation by Gibbons P.C. is indicated.

Local Counsel for Plaintiff Takeda Pharmaceutical Co Ltd:

• Firm: Gibbons P.C. (Newark, New Jersey)
  • Attorneys (Anticipated): While specific attorneys from Gibbons have not yet filed notices of appearance in this case, partners from their Intellectual Property department frequently represent major pharmaceutical clients. In past, similar ANDA cases for Takeda and other life sciences companies, attorneys such as William P. Deni, Jr., have appeared.
  • Role: Local Counsel. The firm is expected to handle filings, court appearances, and provide guidance on the local patent rules and judicial procedures of the highly active District of New Jersey.
  • Relevant Experience: Gibbons P.C. has a long-standing and robust patent litigation practice based in New Jersey, one of the nation's busiest venues for such disputes. The firm has previously partnered with lead counsel to represent Takeda in other significant patent cases, including a successful trial victory defending patents for the multi-billion dollar drug Vyvanse®.

As the case progresses beyond the initial complaint, Takeda's full legal team, including lead trial counsel from a potentially different firm, will make formal appearances. It is common for defendants to be served and for counsel to file a notice of appearance within the first several weeks of a case being filed. No such entries are visible on the public docket as of this date.

Counsel for Defendant Qilu Has Not Yet Appeared

As of May 4, 2026, legal counsel has not yet filed a notice of appearance on behalf of the defendant, Qilu Pharmaceutical (hainan) Co Ltd., in case number 2:26-cv-04121. The case docket, filed on April 17, 2026, does not yet reflect any responsive pleading or appearance by the defendant.

This situation is common in the initial weeks of a patent lawsuit, particularly when the defendant is a foreign corporation. The process of formally serving a complaint on an international defendant under treaties like the Hague Convention can be lengthy. The 21-day deadline for a defendant to file an answer or other responsive pleading under the Federal Rules of Civil Procedure does not begin until service is successfully completed.

Given Qilu's significant presence as a major generic pharmaceutical manufacturer in China and its frequent involvement in U.S. ANDA litigation, it is certain that the company will be represented by experienced U.S. patent counsel. However, until service is effected and counsel makes a formal appearance, their identity is not a matter of public record for this specific case. Publicly available dockets for other recent ANDA cases filed against Qilu in the District of New Jersey and the District of Delaware do not yet show a consistent pattern of representation by a single law firm, as different counsel may be retained depending on the specific technology and patents at issue.